151 related articles for article (PubMed ID: 32050632)
1. Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells.
Akiyama H; Umezawa Y; Watanabe D; Okada K; Ishida S; Nogami A; Miura O
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32050632
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2.
Ishida S; Akiyama H; Umezawa Y; Okada K; Nogami A; Oshikawa G; Nagao T; Miura O
Oncotarget; 2018 Jun; 9(42):26834-26851. PubMed ID: 29928488
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
Akiyama H; Umezawa Y; Ishida S; Okada K; Nogami A; Miura O
Cancer Lett; 2019 Jul; 453():84-94. PubMed ID: 30946869
[TBL] [Abstract][Full Text] [Related]
4. Exploring redox vulnerabilities in JAK2
Lima K; Lopes LR; Machado-Neto JA
Hematol Transfus Cell Ther; 2021; 43(4):430-436. PubMed ID: 32962959
[TBL] [Abstract][Full Text] [Related]
5. Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2
Yuan J; Song J; Chen C; Lv X; Bai J; Yang J; Zhou Y
Invest New Drugs; 2022 Dec; 40(6):1194-1205. PubMed ID: 36044173
[TBL] [Abstract][Full Text] [Related]
6. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2
Machado-Neto JA; Coelho-Silva JL; Santos FPS; Scheucher PS; Campregher PV; Hamerschlak N; Rego EM; Traina F
Invest New Drugs; 2020 Jun; 38(3):733-745. PubMed ID: 31286322
[TBL] [Abstract][Full Text] [Related]
7. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
[TBL] [Abstract][Full Text] [Related]
8. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2
Courdy C; Platteeuw L; Ducau C; De Araujo I; Boet E; Sahal A; Saland E; Edmond V; Tavitian S; Bertoli S; Cougoul P; Granat F; Poillet L; Marty C; Plo I; Sarry JE; Manenti S; Mansat-De Mas V; Joffre C
Blood Cancer J; 2023 Jul; 13(1):106. PubMed ID: 37423955
[TBL] [Abstract][Full Text] [Related]
9. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
10. Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells.
Machado-Neto JA; de Melo Campos P; Favaro P; Lazarini M; da Silva Santos Duarte A; Lorand-Metze I; Costa FF; Saad ST; Traina F
Oncotarget; 2015 Oct; 6(30):29573-84. PubMed ID: 26356819
[TBL] [Abstract][Full Text] [Related]
11. Metformin exerts multitarget antileukemia activity in JAK2
Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
[TBL] [Abstract][Full Text] [Related]
12. DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β.
Nagao T; Oshikawa G; Wu N; Kurosu T; Miura O
PLoS One; 2011; 6(11):e27397. PubMed ID: 22087308
[TBL] [Abstract][Full Text] [Related]
13. Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.
Funakoshi-Tago M; Nagata T; Tago K; Tsukada M; Tanaka K; Nakamura S; Mashino T; Kasahara T
Cell Signal; 2012 Nov; 24(11):2024-34. PubMed ID: 22750290
[TBL] [Abstract][Full Text] [Related]
14. The SMAC mimetic LCL-161 selectively targets JAK2
Craver BM; Nguyen TK; Nguyen J; Nguyen H; Huynh C; Morse SJ; Fleischman AG
Exp Hematol Oncol; 2020; 9():1. PubMed ID: 31908904
[TBL] [Abstract][Full Text] [Related]
15. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
16. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Bongartz H; Hessenkemper W; Müller C; Fensky M; Fritsch J; Mandel K; Behrmann I; Haan C; Fischer T; Feller SM; Schaper F
Cell Signal; 2017 Jul; 35():37-47. PubMed ID: 28365441
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
Funakoshi-Tago M
Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
[TBL] [Abstract][Full Text] [Related]
18. Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
Weber A; Borghouts C; Brendel C; Moriggl R; Delis N; Brill B; Vafaizadeh V; Groner B
Cancers (Basel); 2015 Mar; 7(1):503-37. PubMed ID: 25809097
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
20. WP1130 Enhances TRAIL-Induced Apoptosis through USP9X-Dependent miR-708-Mediated Downregulation of c-FLIP.
Kim S; Woo SM; Min KJ; Seo SU; Lee TJ; Kubatka P; Kim DE; Kwon TK
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30862047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
